Patent: 6,346,517
✉ Email this page to a colleague
Summary for Patent: 6,346,517
Title: | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
Abstract: | This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders. |
Inventor(s): | Wong; Pancras C. (Wilmington, DE), Mousa; Shaker A. (Lincoln University, PA) |
Assignee: | Bristol-Myers Squibb Pharma Company (Princeton, NJ) |
Application Number: | 09/523,395 |
Patent Claims: | see list of patent claims |
Details for Patent 6,346,517
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | ⤷ Try a Trial | 2019-03-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |